Month: September 2025

KH Group PlcInside information 19 September 2025 at 3.20 pm EEST Inside information: Carl Haglund appointed as CEO of KH Group Plc KH Group Plc (”KH Group” or the ”Company”) has appointed Carl Haglund, M.Sc (Econ.), as the new CEO of the Company. Haglund is currently a member of the Board of Directors of the Company. Haglund has also served for many years as Chair of the Board of Directors of Nordic Rescue Group Oy (“Nordic Rescue Group”), a subsidiary of KH Group. Haglund takes up his new position as CEO of the Company as of today 19 September 2025. Haglund will step down from the Board of Directors of the Company as of today but will continue as Chair of the Board of Directors of Nordic Rescue Group. The Board of Directors of KH Group will otherwise continue without changes to its composition. Haglund has served as CEO of Veritas Pension...

Vancouver, Canada, Sept. 19, 2025 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has entered into securities purchase agreements (the “SPAs”) with institutional investors (the “Holders”). Pursuant to the SPAs, the Company may issue and sell, from time to time, convertible promissory notes (the “Notes”) in an aggregate principal amount of up to $10,000,000. Upon the execution of the SPAs (the “First Initial Closing”), the Company issued and sold to the Holders initial Notes in the aggregate principal amount of $555,556 for a purchase price of $500,000. Aegis Capital Corp. acted as financial...

Lunsumio provides high and long-lasting response rates, with approximately two-thirds of patients with a complete response in remission after four years1 Subcutaneous Lunsumio has potential to substantially reduce treatment administration time with an approximately one minute injection, compared with 2-4 hours IV infusion If approved, Lunsumio would be the first treatment available for people with follicular lymphoma after two or more lines of systemic therapy, which is both fixed-duration and subcutaneously administeredBasel, 19 September – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of a subcutaneous (SC) formulation of Lunsumio® (mosunetuzumab) for the treatment of adult patients with relapsed or refractory...

Ra’anana, Israel, Sept. 19, 2025 (GLOBE NEWSWIRE) — Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company focusing on the development of intranasal products, today announced the submission of its full pre-submission (Pre-Sub) package to the U.S. Food and Drug Administration (FDA) for its PL-14 product, designed to help individuals suffering from nasal allergies. The submission includes comprehensive documentation covering manufacturing plans, clinical development strategies, and regulatory pathways. This submission represents a significant progress in Polyrizon’s regulatory strategy, paving the way for potential marketing clearance and addressing a critical unmet need in allergy treatment. Polyrizon’s PL-14 Allergy Blocker is a novel, non-invasive nasal spray that forms a physical barrier designed...

OVATION 3 pivotal Phase 3 trial is currently advancing IMNN-001, with several patients being treated LAWRENCEVILLE, N.J., Sept. 19, 2025 (GLOBE NEWSWIRE) — IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that new translational data from the Phase 2 OVATION 2 Study of IMNN-001, its investigational therapy for the treatment of women with newly diagnosed advanced ovarian cancer, will be presented at the American Association for Cancer Research (AACR) Special Conference in Cancer Research: Advances in Ovarian Cancer Research, being held September 19-21, 2025, in Denver, Colorado. IMNN-001, based on IMUNON’s proprietary TheraPlas® technology platform, is an interleukin-12 (IL-12) DNA plasmid vector incorporated into a novel nanoparticle delivery system,...

CARY, N.C., Sept. 19, 2025 (GLOBE NEWSWIRE) — Fathom Holdings Inc. (Nasdaq: FTHM), a national, technology-driven real estate services platform, today announced the pricing of an underwritten public offering of 3,000,000 shares of its common stock at a price of $2.00 per share. The Company also has granted the underwriter of the offering a 45-day option to purchase up to an additional 15% of the shares of common stock offered in the underwritten public offering on the same terms and conditions. After the underwriting discount and anticipated expenses, the Company expects to receive net proceeds of approximately $5.4 million, not including exercise of the overallotment option. The offering is expected to close on September 22, 2025, subject to customary closing conditions. The Company intends to use the net proceeds from the offering...

NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) — Nuvini Group Limited (Nasdaq: NVNI) (“Nuvini” or the “Company”), a leading technology conglomerate in the Latin American SaaS sector, today announced that Chief Executive Officer Pierre Schurmann will participate in the keynote presentation titled “LatAm Giants Mastering Expansion: The Global Playbook” at Brazil Investment Week in London, UK on September 30, 2025. With a career that includes over 600 startup investments and a legacy of pioneering ventures in tech, marketing, and executive networking, Mr. Schurmann exemplifies the innovative force driving Brazil’s business ecosystem. His leadership at Nuvini reflects a bold strategy of scaling high-potential SaaS companies across Latin America, aligning with the summit’s broader theme of unlocking cross-border investment opportunities...

Bylvay® is the first once-daily ileal bile acid transport inhibitor to be approved as a treatment for pruritus associated with progressive familial intrahepatic cholestasis (PFIC) in Japan, offering a non-surgical treatment option for infants, young children and adults PFIC is a rare and life-threatening liver disease that affects an estimated 100 children and infants in Japan.1Paris, France – 19 September 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted regulatory approval for Bylvay® (odevixibat) for the treatment of pruritus associated with progressive familial intrahepatic cholestasis (PFIC). PFIC is a group of rare genetic disorders in which bile acid accumulates in the liver, leading to progressive liver damage and potentially liver failure. The condition...

Series  RIKB 42 0217Settlement Date  09/24/2025Total Amount Allocated (MM)  1,643All Bids Awarded At (Price / Yield)  78.600 / 6.680Total Number of Bids Received  17Total Amount of All Bids Received (MM)  3,243Total Number of Successful Bids  9Number of Bids Allocated in Full  9Lowest Price / Highest Yield Allocated  78.600 / 6.680Highest Price / Lowest Yield Allocated  79.471 / 6.580Lowest Price / Highest Yield Allocated in Full  78.600 / 6.680Weighted Average of Successful Bids (Price/Yield)  78.769 / 6.660Best Bid (Price / Yield)  79.471 / 6.580Worst Bid (Price / Yield)  78.400 / 6.710Weighted Average of All Bids Received (Price / Yield)  78.630 / 6.680Percentage Partial Allocation (Approximate)  100.00 %Bid to Cover Ratio  1.97